Effects of Acetaminophen Exposure on Outcomes of Patients Receiving Immune Checkpoint Inhibitors for Advanced Non-Small-Cell Lung Cancer: A Propensity Score-Matched Analysis

被引:3
|
作者
Nelli, Fabrizio [1 ]
Virtuoso, Antonella [1 ]
Giannarelli, Diana [2 ]
Fabbri, Agnese [3 ]
Berrios, Julio Rodrigo Giron [3 ]
Marrucci, Eleonora [3 ]
Fiore, Cristina [3 ]
Ruggeri, Enzo Maria [3 ]
机构
[1] Cent Hosp Belcolle, Dept Oncol & Hematol, Thorac Oncol Unit, I-01100 Viterbo, Italy
[2] Fdn Policlin Univ A Gemelli, Ist Ricovero & Cura Carattere Sci IRCCS, Biostat Unit, Sci Directorate, I-00168 Rome, Italy
[3] Cent Hosp Belcolle, Dept Oncol & Hematol, Med Oncol Unit, I-01100 Viterbo, Italy
关键词
non-small-cell lung cancer; immune checkpoint inhibitors; first-line therapy; second-line therapy; acetaminophen; disease control benefit; survival; NONSMALL; ASSOCIATION; RESPONSES; SURVIVAL; EFFICACY; CRITERIA; RECIST;
D O I
10.3390/curroncol30090589
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
(1) Background: Several studies have investigated potential interactions between immune checkpoint inhibitors (ICIs) and commonly prescribed medications. Although acetaminophen (APAP) has not been considered susceptible to interaction with ICIs, recent research has shown that detectable plasma levels of this drug can hinder the efficacy of PD-1/PD-L1 blockade therapies. A reliable assessment of the potential interaction between APAP and ICIs in advanced non-small cell lung cancer (NSCLC) patients would be worthwhile since it is often prescribed in this condition. We sought to evaluate the impact of the concomitant use of APAP in patients with advanced NSCLC on PD-1/PD-L1 blockade using real-world evidence. (2) Methods: This study included consecutive patients with histologically proven stage IV NSCLC who underwent first-line therapy with pembrolizumab as a single agent or in combination with platinum-based chemotherapy, or second-line therapy with pembrolizumab, nivolumab, or atezolizumab. The intensity of APAP exposure was classified as low (therapeutic intake lasting less than 24 h or a cumulative intake lower than 60 doses of 1000 mg) or high (therapeutic intake lasting more than 24 h or a total intake exceeding 60 doses of 1000 mg). The favorable outcome of anti-PD-1/PD-L1 therapies was defined by durable clinical benefit (DCB). Progression-free survival (PFS) and overall survival (OS) were relevant to our efficacy analysis. Propensity score matching (PSM) methods were applied to adjust for differences between the APAP exposure subgroups. (3) Results: Over the course of April 2018 to October 2022, 80 patients were treated with first-line pembrolizumab either as single-agent therapy or in combination with platinum-based chemotherapy. During the period from June 2015 to November 2022, 145 patients were given anti-PD-1/PD-L1 blockade therapy as second-line treatment. Subsequent efficacy analyses relied on adjusted PSM populations in both treatment settings. Multivariate testing revealed that only the level of APAP and corticosteroid intake had an independent effect on DCB in both treatment lines. Multivariate Cox regression analysis confirmed high exposure to APAP and immunosuppressive corticosteroid therapy as independent predictors of shorter PFS and OS in both treatment settings. (4) Conclusions: Our findings would strengthen the available evidence that concomitant intake of APAP blunts the efficacy of ICIs in patients with advanced NSCLC. The detrimental effects appear to depend on the cumulative dose and duration of exposure to APAP. The inherent shortcomings of the current research warrant confirmation in larger independent series.
引用
收藏
页码:8117 / 8133
页数:17
相关论文
共 50 条
  • [1] Impact of previous corticosteroid exposure on outcomes of patients receiving immune checkpoint inhibitors for advanced non-small cell lung cancer: a retrospective observational study
    Nelli, F.
    Virtuoso, A.
    Berrios, J. R. Giron
    Giannarelli, D.
    Fabbri, A.
    Marrucci, E.
    Ruggeri, E. M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (04) : 529 - 537
  • [2] Impact of previous corticosteroid exposure on outcomes of patients receiving immune checkpoint inhibitors for advanced non-small cell lung cancer: a retrospective observational study
    F. Nelli
    A. Virtuoso
    J. R. Giron Berrios
    D. Giannarelli
    A. Fabbri
    E. Marrucci
    E. M. Ruggeri
    Cancer Chemotherapy and Pharmacology, 2022, 89 : 529 - 537
  • [3] Early Changes in LIPI Score Predict Immune-Related Adverse Events: A Propensity Score Matched Analysis in Advanced Non-Small Cell Lung Cancer Patients on Immune Checkpoint Blockade
    Nelli, Fabrizio
    Fabbri, Agnese
    Virtuoso, Antonella
    Giannarelli, Diana
    Berrios, Julio Rodrigo Giron
    Marrucci, Eleonora
    Fiore, Cristina
    Ruggeri, Enzo Maria
    CANCERS, 2024, 16 (02)
  • [4] A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study
    Takada, Kazuki
    Shimokawa, Mototsugu
    Takamori, Shinkichi
    Shimamatsu, Shinichiro
    Hirai, Fumihiko
    Tagawa, Tetsuzo
    Okamoto, Tatsuro
    Hamatake, Motoharu
    Tsuchiya-Kawano, Yuko
    Otsubo, Kohei
    Inoue, Koji
    Yoneshima, Yasuto
    Tanaka, Kentaro
    Okamoto, Isamu
    Nakanishi, Yoichi
    Mori, Masaki
    BMC CANCER, 2022, 22 (01)
  • [5] Synergistic effects of immune checkpoint inhibitors in combination with stereotactic radiosurgery for patients with lung cancer and brain metastases: a propensity score-matched analysis
    Yomo, Shoji
    Oda, Kyota
    Oguchi, Kazuhiro
    JOURNAL OF NEUROSURGERY, 2023, 139 (06) : 1628 - 1637
  • [6] Analysis of immune checkpoint inhibitors for advanced non-small cell lung cancer in patients receiving antacids
    Isono, Taisuke
    Furuno, Hajime
    Onodera, Yoko
    Maruyama, Tomoya
    Takeuchi, Yuki
    Kojima, Ayaka
    Nishida, Takashi
    Kobayashi, Yoichi
    Ishiguro, Takashi
    Takaku, Yotaro
    Kurashima, Kazuyoshi
    Kagiyama, Naho
    RESPIRATORY INVESTIGATION, 2024, 62 (06) : 951 - 959
  • [7] The Therapeutic Effect and Clinical Outcome of Immune Checkpoint Inhibitors on Bone Metastasis in Advanced Non-Small-Cell Lung Cancer
    Asano, Yohei
    Yamamoto, Norio
    Demura, Satoru
    Hayashi, Katsuhiro
    Takeuchi, Akihiko
    Kato, Satoshi
    Miwa, Shinji
    Igarashi, Kentaro
    Higuchi, Takashi
    Yonezawa, Hirotaka
    Araki, Yoshihiro
    Morinaga, Sei
    Saito, Shiro
    Sone, Takashi
    Kasahara, Kazuo
    Tsuchiya, Hiroyuki
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [8] Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients
    Gobbini, Elisa
    Toffart, Anne Claire
    Perol, Maurice
    Assie, Jean-Baptiste
    Duruisseaux, Michael
    Coupez, Dahna
    Dubos, Catherine
    Westeel, Virginie
    Delaunay, Myriam
    Guisier, Florian
    Veillon, Remi
    Gounant, Valerie
    Leprieur, Etienne Giroux
    Vanel, Francois-Roger
    Chaabane, Nouha
    Dansin, Eric
    Babey, Helene
    Decroisette, Chantal
    Barlesi, Fabrice
    Daniel, Catherine
    Fournel, Pierre
    Mezquita, Laura
    Oulkhouir, Youssef
    Canellas, Anthony
    Duchemann, Boris
    Molinier, Olivier
    Alcazer, Vincent
    Moro-Sibilot, Denis
    Levra, Matteo Giaj
    CLINICAL LUNG CANCER, 2020, 21 (05) : E497 - E510
  • [9] Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors
    Afzal, Muhammad Z.
    Dragnev, Konstantin
    Sarwar, Tayyaba
    Shirai, Keisuke
    LUNG CANCER MANAGEMENT, 2019, 8 (02)
  • [10] Combing Immune Checkpoint Inhibitors with Radiotherapy in Advanced Non-small-cell Lung Cancer
    Zou, Y.
    Chen, Y.
    Zhou, X.
    Gong, Y.
    Xu, Y.
    Zou, B.
    Peng, F.
    Huang, M.
    Lu, Y.
    Liu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S625 - S625